Skip to Content
Merck
All Photos(4)

Documents

P6188

Sigma-Aldrich

Prostaglandin I2 sodium salt

≥96% (HPLC), synthetic, powder

Synonym(s):

(5Z,9α,11α,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium salt, Epoprostenol sodium salt, PGI2-Na, Prostacyclin sodium salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H31NaO5
CAS Number:
Molecular Weight:
374.45
Beilstein:
6472195
EC Number:
UNSPSC Code:
12352401
eCl@ss:
42020658
PubChem Substance ID:
NACRES:
NA.77

biological source

synthetic

Quality Level

Assay

≥96% (HPLC)

form

powder

color

white to off-white

solubility

H2O: 1 mg/mL (Hydrolyzes to 6-ketoprostaglandin F in aqueous solution.)
ethanol: 50 mg/mL

functional group

carboxylic acid
hydroxyl

shipped in

ambient

storage temp.

−20°C

SMILES string

CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@](O/2)([H])[C@]1([H])CC2=C\CCCC(O)=O.[Na]

InChI

1S/C20H32O5.Na/c1-2-3-4-8-15(21)10-11-16-17(22)12-18-20(16)14(13-25-18)7-5-6-9-19(23)24;/h7,10-11,15-18,20-22H,2-6,8-9,12-13H2,1H3,(H,23,24);/q;+1/p-1/b11-10+,14-7-;/t15-,16-,17+,18-,20+;/m0./s1

InChI key

OURCVRVJQMLUNA-QFDVFERUSA-M

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Prostaglandin I2 sodium salt has been used:
  • in the preparation of stock solution for platelet washing procedure
  • as supplement in platelet-rich-plasma, for platelet preparation
  • to prevent platelet activation

Biochem/physiol Actions

Prostacyclin is a short-lived product of the cyclooxygenase pathway in vascular endothelial cells. It is a potent inhibitor of platelet aggregation by antagonizing thromboxane A2 and stimulating platelet adenylyl cyclase. Nitric oxide is also produced in vascular endothelium where it inhibits platelet aggregation, regulates inducible cyclooxygenase production, and may work synergistically with prostacyclin to attenuate the thrombotic process. Prostacyclin is vasoprotective, protecting arterial walls from injury-induced lesions and cytoprotective in the liver and gastrointestinal tract.
Prostacyclin therapy improves hemodynamics in pulmonary arterial hypertension.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Seung-Jae Joo et al.
Korean circulation journal, 45(5), 378-385 (2015-09-29)
Residual platelet reactivity in patients who are taking clopidogrel is commonly measured with VerifyNow assay, which is based on the principle of light transmission aggregometry. However, to evaluate the residual platelet reactivity, it would be more accurate if the reactivity
G J Dusting et al.
Clinical and experimental pharmacology & physiology. Supplement, 25, S34-S41 (1998-11-11)
1. Nitric oxide (NO) has important roles in physiological vasodilatation, cytotoxicity and vascular disease. Nitric oxide and prostacyclin (PGI2), both released from the endothelium, act synergistically to inhibit platelet aggregation and adhesion. These autacoids also inhibit the adhesion and migration
Anna-Karin Larsson-Callerfelt et al.
Respiratory research, 14, 21-21 (2013-02-15)
Prostacyclin analogs are potent vasodilators and possess anti-inflammatory properties. However, the effect of prostacyclin on extracellular matrix (ECM) in COPD is not well known. Collagen fibrils and proteoglycans are essential ECM components in the lung and fibroblasts are key players
Effects of ethanol on aggregation, serotonin release, and amyloid precursor protein processing in rat and human platelets
Ehrlich D and Humpel C
Platelets, 25(1), 16-22 (2014)
Paola Vitale et al.
Journal of medicinal chemistry, 56(11), 4277-4299 (2013-05-09)
3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design a new series of 3,4-diarylisoxazoles in order to improve its biochemical COX-1 selectivity and antiplatelet efficacy. Structure-activity relationships were studied using human whole blood assays for COX-1 and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service